ADEPT: Phase II neo-adjuvant study of Androgen Deprivation Therapy (Degarelix) and Erdafitinib in high-risk localized prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Degarelix (Primary) ; Erdafitinib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADEPT
- 19 Jul 2019 Planned End Date changed from 1 Jan 2020 to 30 Sep 2019.
- 19 Jul 2019 Planned primary completion date changed to 31 Aug 2019.
- 09 Apr 2019 Status changed from not yet recruiting to recruiting.